Sildenafil, Trazodone Tablets Recalled After Being Packaged Together
AvKARE says it is not aware of any patients being harmed by the recalled products
AvKARE says it is not aware of any patients being harmed by the recalled products
Risk up for nonelderly adults with augmentation with newer antipsychotic versus second antidepressant.
The 510(k) clearance allows for modification of the labeling of the previously authorized pharmacogenetics report.
The approval was based on the ASPIRE I and II trials that compared the efficacy and safety of esketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, to placebo in 449 adults with moderate to severe MDD who had active suicidal ideation and intent.
Incidence and recurrence of depression, change in mood scores did not differ from placebo for adults ≥50.
An FDA database revealed that people who receive Botox injections report less depression.
All seven studies demonstrated significant improvements in one or more of the outcomes measured
No significant difference seen in incidence rate of new CES-D-10 scores of ≥8 for aspirin, placebo
Presently, clinicians should be urged to view genetics as an additional tool in choosing prescriptions for MDD, as opposed to a replacement for complete clinical evaluation.
Biota Biosciences announced the voluntary recall of CBD Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables due to the products being marketed without the approval of the FDA.